A Phase I Study to Assess the Pharmacokinetics of Olorofim in Subjects With Hepatic Impairment
Status:
Recruiting
Trial end date:
2021-09-30
Target enrollment:
Participant gender:
Summary
A single oral dose study to investigate the PK and safety of olorofim in mild and moderately
hepatically impaired subjects compared to subjects with normal hepatic function.